公开(公告)号：US20090214541A1

公开(公告)日：2009-08-27

申请号：US12086725

申请日：2006-12-15

Applicant: Stephen D. Gillies ,  David Azria ,  Christel Larbouret ,  Andre Pelegrin

Inventor： Stephen D. Gillies ,  David Azria ,  Christel Larbouret ,  Andre Pelegrin

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2863 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31

Abstract: The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

Abstract translation: 本发明涉及用于治疗癌症的抗EGFR抗体和抗Her2抗体的组合使用，特别适用于表达高水平的EGFR型和低水平的HER2的癌症。 本发明特别涉及针对HER2受体的单克隆抗体“曲妥珠单抗”（HERCEPTIN），当与针对EGF受体的单克隆抗体“matuzumab”（hmAB 425，EMD 72000）组合时，其效力可以显着增加 。 联合治疗适用于患有具有所述受体分布的癌症的患者，优选胰腺癌。